Evaluation of clinical outcomes of anidulafungin for the treatment of candidemia in hospitalized critically ill patients with obesity: A multicenter, retrospective cohort study.
Int J Infect Dis
; 148: 107234, 2024 Sep 04.
Article
in En
| MEDLINE
| ID: mdl-39241957
ABSTRACT
OBJECTIVES:
To evaluate the clinical outcomes of anidulafungin for candidemia treatment in critically ill patients with obesity.METHODS:
A multicenter, retrospective cohort study was conducted in Saudi Arabia for critically ill adults with candidemia who received anidulafungin. Patients with obesity have a body mass index ≥30 kg/m2. The primary outcome was the clinical cure rate.RESULTS:
A total of 146 patients were included, 64 of whom were obese. There were no statistically significant differences in the clinical cure rate (P = 0.63), microbiological cure rate (P = 0.27), or the median time for a clinical cure (P = 0.13) for patients with obesity compared to non-obese patients. The median time for a microbiological cure was longer in non-obese patients than in patients with obesity (P = 0.04). The median hospital length of stay and the median mechanical ventilation durations were numerically longer in patients with obesity.CONCLUSIONS:
Clinical and microbiological cure rates and time for clinical cure were statistically similar for both groups. Considering the study's limitations (especially with a small sample size), it is uncertain if patients with obesity have similar effectiveness to non-obese patients. Future studies with larger sample sizes are warranted to evaluate if obesity negatively impacts anidulafungin's clinical outcomes for candidemia.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Int J Infect Dis
/
Int. j. infect. dis
/
International journal of infectious diseases
Journal subject:
DOENCAS TRANSMISSIVEIS
Year:
2024
Document type:
Article
Affiliation country:
Saudi Arabia
Country of publication:
Canada